In order to determine the effect HSP90 function has on MYC expression in Burkitt lymphoma, we disrupted HSP90 function by using the commercially available HSP90 inhibitor, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), a derivative of geldanamycin [16]. Here, MYC is linked to Burkitt lymphoma.